A. Cseh

发表

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Markus J. Bauer, S. Zöchbauer-Müller, H. Prosch, 2021, Frontiers in Oncology.

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

J. Shih, Keunchil Park, Yuh-Min Chen, 2021, International Journal of Clinical Oncology.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

F. Cappuzzo, Chun-Ming Tsai, M. Schuler, 2018, Future oncology.

Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib

D. Reardon, N. Gibson, P. Kavan, 2022, OncoTargets and therapy.

NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents.

A. Drilon, R. Schlenk, C. Heining, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.

S. Novello, F. de Marinis, R. Dziadziuszko, 2020, Lung cancer.

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

J. Shih, S. Peters, G. Chang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.

A. Drilon, R. Schlenk, C. Heining, 2020, The oncologist.

Efficacy and Safety Results of the Afatinib Expanded Access Program

Edward S. Kim, B. Halmos, A. Spira, 2017, Oncology and Therapy.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

E. Felip, A. Ardizzoni, Y. Min, 2021, EClinicalMedicine.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

K. Syrigos, E. Felip, J. Soria, 2018, JAMA oncology.

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

W. Mason, D. Eisenstat, S. Phuphanich, 2014, Neuro-oncology.

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial

C. Mcbain, F. Saran, M. Brada, 2021, Journal of Neuro-Oncology.

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report

D. Reardon, N. Gibson, P. Kavan, 2015, Oncotarget.

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

S. Thongprasert, R. Gaafar, M. Schenker, 2019, Lung cancer management.

Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer

A. Marchetti, F. Cappuzzo, A. Santoro, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

B. Peil, N. Gibson, Wei Li, 2018, OncoTargets and Therapy.

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Jing Zhu, Ying Cheng, Yi-long Wu, 2022, Targeted Oncology.

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

O. Burghuber, M. Filipits, H. Prosch, 2018, Targeted Oncology.

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.

Hanxiao Chen, H. Bai, Yahui Tian, 2022, Future oncology.

P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

E. Felip, J. Soria, A. Ardizzoni, 2017 .

P2.03-025 Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib

O. Burghuber, M. Filipits, M. Hochmair, 2017 .